DISCLAIMER

This material includes forward-looking statements based on assumptions and beliefs in light of information currently available to the Astellas and subject to significant risks and uncertainties.

This material contains information on pharmaceuticals (including compounds in research or under development) and other matters. Notwithstanding the foregoing, Astellas makes no representations, warranties, assurances or guarantees of any kind or nature whatsoever, whether expressed or implied, regarding the information in the materials (including, without limitation, no representations, warranties, assurances or guarantees as to the accuracy, sufficiency or completeness of any information, as to whether Astellas has rights to any such information or pharmaceuticals/compounds, as to whether any third party has or does not have any rights to any of such information or pharmaceuticals/compounds, as to the safety, efficacy, or effectiveness of any preparations described in this material, as to the regulatory status of or potential for regulatory agency action regarding any pharmaceuticals/compounds described in this material, or as to any uses, including unapproved uses, of any such preparations in any fashion). This material does not provide medical advice of any kind. Astellas undertakes no obligation or duty to change, remove, add, clarify, correct or update any information in the materials at any time.
<table>
<thead>
<tr>
<th>Items</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product name</td>
<td>ASP1007</td>
</tr>
<tr>
<td>Mechanism of Action</td>
<td>T cell-mediated CD37-positive tumor killing</td>
</tr>
<tr>
<td>Modality</td>
<td>Antibody</td>
</tr>
<tr>
<td>Target Indication</td>
<td>Non-Hodgkin lymphoma (diffuse large B cell lymphoma)</td>
</tr>
<tr>
<td>Latest development phase</td>
<td>Preclinical</td>
</tr>
</tbody>
</table>
ASP1007 is a bispecific T cell recruiting antibody which targets CD37-expressing cells.

Different from natural antibodies, T cell recruiting antibodies can redirect T cells to specific tumor antigens and activate T cells directly.

CD37 most highly expressed by mature B-cells, although other immune cells express CD37 to a lesser degree. It is absent in the earliest stages of B cell development and is lost again following differentiation into plasma cells.

This pattern is mirrored in B cell malignancies: CD37 is expressed in mature B cell neoplasms, including diffuse large B cell lymphoma and other non-Hodgkin lymphomas.

ASP1007 SUMMARY OF PRECLINICAL RESULTS

**Pharmacology**
- ASP1007 induced in vitro redirected T cell cytotoxicity against SU-DHL6, a CD37-expressing diffuse large B cell lymphoma cell line.
- ASP1007 showed killing activity against B cells but not against T cells when cultured with PBMC from healthy volunteers.
- ASP1007 showed in vivo antitumor efficacy in human PBMC engrafted SU-DHL6 xenograft mouse model.

**ADME**
- No critical concerns were found in PK profiles of ASP1007 in cynomolgus monkeys.
- Analytical method validation for GLP toxicity study and clinical trials are not yet performed.

**Toxicology**
- No GLP toxicity study has been conducted yet.
- No critical concern has been identified in a single dosing toxicity study with cynomolgus monkeys (Non-GLP).

PBMC: peripheral blood mononuclear cells
Patent covering ASP1007

- Priority application (filed on May 12, 2022) for the substance
  - This priority application is maintained in Japan. The plan to file foreign countries is TBD.